William Blair reiterates Outperform on Tarsus Pharmaceuticals stock By Investing.com

Tarsus reported FY net product sales of $451.4M, up 147% year-over-year, with Q4 product sales of $151.7M while remaining unprofitable due to heavy commercialization spending. William Blair reiterated an Outperform and expects U.S. XDEMVY sales to exceed $1B by 2028; analyst price targets range from $88 to $105. The company received a $15M milestone after TP-03/XDEMVY approval in Greater China, providing international upside; shares dipped slightly in aftermarket trading.

Analysis

The commercial momentum creates a structural moat far beyond a single quarterly beat: once prescribing habits form inside optometry channels and payers accept a specialty-code workflow, marginal marketing dollars buy accelerating unit volume while fixed SG&A leverages rapidly. This implies a nonlinear profitability pathway — heavy near-term investment can flip to outsized free cash flow within 24–36 months if stickiness and insurance coverage persist, making the ask-rate for incremental R&D/SG&A fairly attractive from a capital allocation standpoint.

Second-order winners include specialty ophthalmic CMOs, blister/eye-drop packaging vendors, and optometry group consolidators that can capture dispensing economics; losers are compounding pharmacies and legacy topical OTC plays that lack a formal reimbursement pathway. A notable fragility is commercial reliance on a small set of high-frequency prescribers and partner execution in foreign markets — any concentration-driven churn or partner miscues will transmit quickly to revenue recognition and sentiment.

Key risk vectors that can reverse the trade: a surprise safety or tolerability signal, a payer-driven step-edit that forces cheaper alternatives, or manufacturing bottlenecks that delay supply during the critical repeat-prescription window. Near-term catalysts to watch are successive physician-level prescribing metrics and payer formulary updates over the next 2–6 quarters; medium-term value unlocks cluster around international rollouts and gross-margin expansion as scale dilutes fixed commercial spend.

Key Decisions for Investors

• Buy TARS equity (2–3% NAV), horizon 12 months. Rationale: capture asymmetric upside from commercial leverage; initial stop-loss at -30% and add-on if sequential prescribing KPIs beat two consecutive quarters. Target: 1.5–3x equity return if adoption trajectory holds; downside capped by stop and active hedging.
• Buy a 12–18 month call spread on TARS (ATM long call financed by selling a higher strike). Structure limits premium outlay while retaining convex upside to adoption beats. Max loss = net premium; target 100–200% return if uptake accelerates and volatility compresses.
• Pair hedge: buy TARS shares and purchase 6–9 month OTM put protection or a put spread (cost-effective insurance) sized to limit portfolio drawdown to 10% of position. Use the hedge through the next two earnings cycles; unwind if prescriber metrics confirm persistent demand.
• Event trigger rule: if sequential commercial KPIs (new prescribers and Rx refill rates) miss consensus by >15% in any quarter, reduce exposure by 50% within 48 hours and reassess; conversely, if two consecutive quarters exceed targets by >15%, add 50% to position and consider rolling call spreads to monetize upside.